Biohaven is up 8.6%, or $1.13 to $14.22.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on BHVN:
- Biohaven price target raised to $31 from $27 at Cantor Fitzgerald
- Biohaven Reports Fourth Quarter and Full Year 2022 Financial Results and Reports Recent Business Developments
- Biohaven acquires rights to develop dual inhibitor of TYK2 and JAK1
- Biohaven to present anti-seizure results of BHV-7000
- Biohaven’s taldefgrobep alfa receives FDA Fast Track designation for SMA